Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity

被引:84
作者
So, A
Duffy, DL
Gordon, RD
Jeske, YWA
Lin-Su, K
New, MI
Stowasser, M [1 ]
机构
[1] Univ Queensland, Dept Med, Hypertens Unit, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia
[2] Mt Sinai Sch Med, Adrenal Steroid Disorders Program, New York, NY USA
关键词
familial; primary aldosteronism; hypertension; linkage; genetic;
D O I
10.1097/01.hjh.0000174299.66369.26
中图分类号
R6 [外科学];
学科分类号
1002 [临床医学]; 100210 [外科学];
摘要
Background Familial hyperaldosteronism type II (FH-II) is characterized by the familial occurrence of primary aldosteronism; unlike FH-I, it is not glucocorticoid-remediable and not associated with the hybrid CYP11B1/CYP11B2 gene mutation. Linkage to a 5-Mbp region of chromosome 7p22 was previously reported in an Australian family with eight affected members. Mutations in the exons or intron-exon boundaries of PRKAR1B (7p22, closely related to PRKAR1A, which is mutated in Carney complex) have been excluded in this family. Objective To refine the region of linkage, and to seek evidence of linkage in a South American family and in three other Australian families with FH-II, using seven closely spaced markers at 7p22. Methods To establish phenotypes (affected, uncertain or unaffected), blood pressure, plasma aldosterone and plasma renin (activity or concentration) were measured and the aldosterone: renin ratio (ARR) calculated. Individuals with consistently increased ARR underwent fludrocortisone suppression testing. The genotypes of the five pedigrees were analysed using seven closely spaced microsatellite markers at 7p22, and two-point and multipoint logarithm of odds (LOD) scores were calculated to assess linkage with FH-II. Results The combined multipoint LOD score for three families (the original Australian, the South American and a new Australian family) showing linkage at 7p22 was highly significant at 4.61 (theta = 0) for markers D7S462 and D7S517. A newly found recombination event in the first Australian family narrowed the area of linkage by 1.8 Mbp, permitting exclusion of approximately half the candidate genes in the originally reported locus. It was not possible to demonstrate linkage at the 7p22 region in the remaining two Australian families. Conclusion This study provides further evidence for linkage of FH-II to 7p22, refines the locus, and supports the notion that FH-II may be genetically heterogeneous.
引用
收藏
页码:1477 / 1484
页数:8
相关论文
共 33 条
[1]
Phenotypic and genetic heterogeneity of familial hyperkalaemic hypertension (Gordon syndrome) [J].
Achard, JM ;
Disse-Nicodeme, S ;
Fiquet-Kempf, B ;
Jeunemaitre, X .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2001, 28 (12) :1048-1052
[2]
Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer [J].
Carmeci, C ;
Thompson, DA ;
Ring, HJZ ;
Francke, U ;
Weigel, RJ .
GENOMICS, 1997, 45 (03) :607-617
[3]
EXPRESSION CDNA CLONING OF A TRANSFORMING GENE ENCODING THE WILD-TYPE G-ALPHA-12 GENE-PRODUCT [J].
CHAN, AML ;
FLEMING, TP ;
MCGOVERN, ES ;
CHEDID, M ;
MIKI, T ;
AARONSON, SA .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (02) :762-768
[4]
Genomic structure of the human gene for protein kinase A regulatory subunit R1-beta (PRKAR1B) on 7p22: no evidence for mutations in familial hyperaldosteronism type II in a large affected kindred [J].
Elphinstone, MS ;
Gordon, RD ;
So, A ;
Jeske, YWA ;
Stratakis, CA ;
Stowasser, M .
CLINICAL ENDOCRINOLOGY, 2004, 61 (06) :716-723
[5]
Retention of heterozygosity at chromosome 7p22 and 11q13 in aldosterone-producing tumours of patients with familial hyperaldosteronism not remediable by glucocorticoids [J].
Fallo, F ;
Pilon, C ;
Barzon, L ;
Pistorello, M ;
Sonino, N ;
Veglio, F ;
Mulatero, P .
JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (11) :829-830
[6]
Primary hyperaldosteronism in essential hypertensives:: Prevalence, biochemical profile, and molecular biology [J].
Fardella, CE ;
Mosso, L ;
Gómez-Sánchez, C ;
Cortés, P ;
Soto, J ;
Gómez, L ;
Pinto, M ;
Huete, A ;
Oestreicher, E ;
Foradori, A ;
Montero, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05) :1863-1867
[7]
HIGH-INCIDENCE OF PRIMARY ALDOSTERONISM IN 199 PATIENTS REFERRED WITH HYPERTENSION [J].
GORDON, RD ;
STOWASSER, M ;
TUNNY, TJ ;
KLEMM, SA ;
RUTHERFORD, JC .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1994, 21 (04) :315-318
[8]
CLINICAL AND PATHOLOGICAL DIVERSITY OF PRIMARY ALDOSTERONISM, INCLUDING A NEW FAMILIAL VARIETY [J].
GORDON, RD ;
STOWASSER, M ;
TUNNY, TJ ;
KLEMM, SA ;
FINN, WL ;
KREK, AL .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1991, 18 (05) :283-286
[9]
Familial forms broaden the horizons for primary aldosteronism [J].
Gordon, RD ;
Stowasser, M .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1998, 9 (06) :220-227
[10]
PRIMARY ALDOSTERONISM - HYPERTENSION WITH A GENETIC-BASIS [J].
GORDON, RD ;
KLEMM, SA ;
TUNNY, TJ ;
STOWASSER, M .
LANCET, 1992, 340 (8812) :159-161